Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in Moderately to Severely Active Ulcerative Colitis
NCT07196748Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Peptides, Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of icotrokinra in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Oct 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07196748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196748.